(Q46858687)

English

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study

scientific article published on 26 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Geneviève Chêne

12

object named as

Geneviève Chêne

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

11

object named as

Odile Launay

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

author name string

Gilles Pialoux

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Hakim Hocini

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Sophie Pérusat

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Benjamin Silberman

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Dominique Salmon-Ceron

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Laurence Slama

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Valérie Journot

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Emmanuelle Mathieu

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Christophe Gaillard

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Karine Petitprez

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

ANRS VAC14 Study Group

13

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

language of work or name

0 references

publication date

26 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

26

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

21

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

2657-2666

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Mucosal AIDS vaccines: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

HIV vaccines: new frontiers in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Mucosal vaccination strategies for women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

A review of vaccine research and development: the human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Mucosal HIV vaccines: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Optimal delivery of vaccines: clinical pharmacokinetic considerations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Female genital tract immunization: evaluation of candidate immunoadjuvants on epithelial cell secretion of CCL20 and dendritic/Langerhans cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

A novel cationic liposome reagent for efficient transfection of mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Safety profile of recombinant canarypox HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.002

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.11.002

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/18068876

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46858687&oldid=2135141328"